Cargando…
AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software
Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Metho...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399961/ https://www.ncbi.nlm.nih.gov/pubmed/28491280 http://dx.doi.org/10.12688/f1000research.10569.2 |
_version_ | 1783230738612617216 |
---|---|
author | Weiss, Shennan Aibel Asadi-Pooya, Ali A Vangala, Sitaram Moy, Stephanie Wyeth, Dale H Orosz, Iren Gibbs, Michael Schrader, Lara Lerner, Jason Cheng, Christopher K Chang, Edward Rajaraman, Rajsekar Keselman, Inna Churchman, Perdro Bower-Baca, Christine Numis, Adam L Ho, Michael G Rao, Lekha Bhat, Annapoorna Suski, Joanna Asadollahi, Marjan Ambrose, Timothy Fernandez, Andres Nei, Maromi Skidmore, Christopher Mintzer, Scott Eliashiv, Dawn S Mathern, Gary W Nuwer, Marc R Sperling, Michael Engel Jr, Jerome Stern, John M |
author_facet | Weiss, Shennan Aibel Asadi-Pooya, Ali A Vangala, Sitaram Moy, Stephanie Wyeth, Dale H Orosz, Iren Gibbs, Michael Schrader, Lara Lerner, Jason Cheng, Christopher K Chang, Edward Rajaraman, Rajsekar Keselman, Inna Churchman, Perdro Bower-Baca, Christine Numis, Adam L Ho, Michael G Rao, Lekha Bhat, Annapoorna Suski, Joanna Asadollahi, Marjan Ambrose, Timothy Fernandez, Andres Nei, Maromi Skidmore, Christopher Mintzer, Scott Eliashiv, Dawn S Mathern, Gary W Nuwer, Marc R Sperling, Michael Engel Jr, Jerome Stern, John M |
author_sort | Weiss, Shennan Aibel |
collection | PubMed |
description | Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Methods: A blinded investigation used 23 EEG recordings of seizures from 8 patients. Each recording was uninterpretable with digital filtering because of muscle artifact and processed using AR1 and AR2 and reviewed by 26 EEG specialists. EEG readers assessed seizure-onset time, lateralization, and region, and specified confidence for each determination. The two methods were validated on the basis of the number of readers able to render assignments, confidence, the intra-class correlation (ICC), and agreement with other clinical findings. Results: Among the 23 seizures, two-thirds of the readers were able to delineate seizure-onset time in 10 of 23 using AR1, and 15 of 23 using AR2 (p<0.01). Fewer readers could lateralize seizure-onset (p<0.05). The confidence measures of the assignments were low (probable-unlikely), but increased using AR2 (p<0.05). The ICC for identifying the time of seizure-onset was 0.15 (95% confidence interval (CI), 0.11-0.18) using AR1 and 0.26 (95% CI 0.21-0.30) using AR2. The EEG interpretations were often consistent with behavioral, neurophysiological, and neuro-radiological findings, with left sided assignments correct in 95.9% (CI 85.7-98.9%, n=4) of cases using AR2, and 91.9% (77.0-97.5%) (n=4) of cases using AR1. Conclusions: EEG artifact reduction methods for localizing seizure-onset does not result in high rates of interpretability, reader confidence, and inter-reader agreement. However, the assignments by groups of readers are often congruent with other clinical data. Utilization of the AR2 software method may improve the validity of ictal EEG artifact reduction. |
format | Online Article Text |
id | pubmed-5399961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | F1000Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-53999612017-05-09 AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software Weiss, Shennan Aibel Asadi-Pooya, Ali A Vangala, Sitaram Moy, Stephanie Wyeth, Dale H Orosz, Iren Gibbs, Michael Schrader, Lara Lerner, Jason Cheng, Christopher K Chang, Edward Rajaraman, Rajsekar Keselman, Inna Churchman, Perdro Bower-Baca, Christine Numis, Adam L Ho, Michael G Rao, Lekha Bhat, Annapoorna Suski, Joanna Asadollahi, Marjan Ambrose, Timothy Fernandez, Andres Nei, Maromi Skidmore, Christopher Mintzer, Scott Eliashiv, Dawn S Mathern, Gary W Nuwer, Marc R Sperling, Michael Engel Jr, Jerome Stern, John M F1000Res Software Tool Article Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Methods: A blinded investigation used 23 EEG recordings of seizures from 8 patients. Each recording was uninterpretable with digital filtering because of muscle artifact and processed using AR1 and AR2 and reviewed by 26 EEG specialists. EEG readers assessed seizure-onset time, lateralization, and region, and specified confidence for each determination. The two methods were validated on the basis of the number of readers able to render assignments, confidence, the intra-class correlation (ICC), and agreement with other clinical findings. Results: Among the 23 seizures, two-thirds of the readers were able to delineate seizure-onset time in 10 of 23 using AR1, and 15 of 23 using AR2 (p<0.01). Fewer readers could lateralize seizure-onset (p<0.05). The confidence measures of the assignments were low (probable-unlikely), but increased using AR2 (p<0.05). The ICC for identifying the time of seizure-onset was 0.15 (95% confidence interval (CI), 0.11-0.18) using AR1 and 0.26 (95% CI 0.21-0.30) using AR2. The EEG interpretations were often consistent with behavioral, neurophysiological, and neuro-radiological findings, with left sided assignments correct in 95.9% (CI 85.7-98.9%, n=4) of cases using AR2, and 91.9% (77.0-97.5%) (n=4) of cases using AR1. Conclusions: EEG artifact reduction methods for localizing seizure-onset does not result in high rates of interpretability, reader confidence, and inter-reader agreement. However, the assignments by groups of readers are often congruent with other clinical data. Utilization of the AR2 software method may improve the validity of ictal EEG artifact reduction. F1000Research 2017-04-04 /pmc/articles/PMC5399961/ /pubmed/28491280 http://dx.doi.org/10.12688/f1000research.10569.2 Text en Copyright: © 2017 Weiss SA et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Software Tool Article Weiss, Shennan Aibel Asadi-Pooya, Ali A Vangala, Sitaram Moy, Stephanie Wyeth, Dale H Orosz, Iren Gibbs, Michael Schrader, Lara Lerner, Jason Cheng, Christopher K Chang, Edward Rajaraman, Rajsekar Keselman, Inna Churchman, Perdro Bower-Baca, Christine Numis, Adam L Ho, Michael G Rao, Lekha Bhat, Annapoorna Suski, Joanna Asadollahi, Marjan Ambrose, Timothy Fernandez, Andres Nei, Maromi Skidmore, Christopher Mintzer, Scott Eliashiv, Dawn S Mathern, Gary W Nuwer, Marc R Sperling, Michael Engel Jr, Jerome Stern, John M AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software |
title | AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software |
title_full | AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software |
title_fullStr | AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software |
title_full_unstemmed | AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software |
title_short | AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software |
title_sort | ar2, a novel automatic muscle artifact reduction software method for ictal eeg interpretation: validation and comparison of performance with commercially available software |
topic | Software Tool Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399961/ https://www.ncbi.nlm.nih.gov/pubmed/28491280 http://dx.doi.org/10.12688/f1000research.10569.2 |
work_keys_str_mv | AT weissshennanaibel ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT asadipooyaalia ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT vangalasitaram ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT moystephanie ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT wyethdaleh ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT orosziren ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT gibbsmichael ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT schraderlara ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT lernerjason ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT chengchristopherk ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT changedward ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT rajaramanrajsekar ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT keselmaninna ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT churchmanperdro ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT bowerbacachristine ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT numisadaml ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT homichaelg ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT raolekha ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT bhatannapoorna ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT suskijoanna ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT asadollahimarjan ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT ambrosetimothy ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT fernandezandres ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT neimaromi ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT skidmorechristopher ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT mintzerscott ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT eliashivdawns ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT matherngaryw ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT nuwermarcr ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT sperlingmichael ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT engeljrjerome ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware AT sternjohnm ar2anovelautomaticmuscleartifactreductionsoftwaremethodforictaleeginterpretationvalidationandcomparisonofperformancewithcommerciallyavailablesoftware |